Monoclonal antibodies (mAbs) are powerful therapeutics that address unmet treatment needs in a wide range of serious diseases. Local delivery of mAbs used in the treatment of lung indications via the inhalation route may help reduce dose, limit systemic exposure of healthy tissues, and lessen adverse events while improving patient compliance and lowering the cost of treatment. This webinar describes the use of spray drying to manufacture dry-powder inhaled formulations of a monoclonal antibody for lung cancer. The resulting formulation was shown to be shelf-stable at ambient temperature, have aerosol properties targeted for delivery to the deep lung, and was efficacious at reducing tumor burden in a rat model of non-small-cell lung cancer.
You may also be interested in:
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center